Drug-eluting Balloon Catheters Market Forecasts to 2030 – Global Analysis By Product (Coronary Artery Balloon Catheters and Peripheral Vascular Balloon Catheters), Drug, Material, End User and By Geography
According to Stratistics MRC, the Global Drug-eluting Balloon Catheters Market is accounted for $651.0 million in 2023 and is expected to reach $1343.2 million by 2030 growing at a CAGR of 10.9% during the forecast period. Medical devices called drug-eluting balloon catheters (DEBs) are used in interventional cardiology to treat peripheral arterial disease (PAD) and coronary artery disease (CAD). The purpose of these catheters is to administer medication straight to the damaged blood vessel walls in order to stop restenosis, or the constriction of blood vessels after angioplasty treatments. With developments in drug coatings, catheter technology, and continuing clinical research focused on improving patient outcomes and safety, the market for drug-eluting balloon catheters is continually changing.
According to the American Heart Association 2021 report, peripheral artery disease (PAD) affects more than 200 million people worldwide and is associated with high mortality and morbidity. Moreover, the increasing geriatric population, which is prone to cardiovascular diseases and growing healthcare spending are projected to bolster market growth
Market Dynamics:Driver:Prevalence of cardiovascular diseases
The number of individuals in need of interventional therapies to control arterial blockages grows in tandem with the frequency of cardiovascular disorders. For these patients, drug-eluting balloon catheters provide an efficient therapeutic alternative that may result in an increase in the number of procedures using these devices. Additionally, healthcare cost is influenced by the financial burden of cardiovascular illnesses, which includes follow-up care, hospital stays, and therapies. Thus drug-eluting balloon catheters are one example of an innovative and successful treatment that may be more widely used if it can be demonstrated to save long-term healthcare expenditures by reducing restenosis and recurring procedures which encourage the growth of the market.
Restraint:Limited clinical evidence in some lesion types
There may be fewer effective treatment choices available to healthcare practitioners for particular lesion types if there is limited clinical data supporting the use of drug-eluting balloon catheters. This restriction may result in patients with certain arterial lesions not receiving the best care possible, especially if these are thought to be a potentially good alternative but have no solid data to support their use. Even while these systems could be beneficial in some circumstances, they might choose more well-established therapies with more evidence, missing out on chances to improve patient care thereby propel the growth of the market.
Opportunity:Expanding clinical evidence
Drug-eluting balloon catheters are safe, effective, and have good long-term results; this data supports their use and encourages healthcare practitioners to use them. Increased clinical data demonstrating the advantages of drug-eluting balloon catheters can have a favourable impact on healthcare payers' judgments about reimbursement. More proof of better patient outcomes might support reimbursement rules that are more favourable, increasing market access and device usage.
Threat:Cost considerations and reimbursement challenges
Patients' access to drug-eluting balloon catheters may be hampered by payment issues, especially in areas or healthcare systems with unfavourable coverage or reimbursement laws. Due to this restriction, patients may not have equal access to cutting-edge therapies, which might have an effect on their prognosis depending on their insurance status or region. Difficulties with reimbursement or hold-ups in receiving positive coverage decisions might hinder drug-eluting balloon catheters market penetration and acceptance.
Covid-19 ImpactMany hospitals and healthcare facilities gave priority to COVID-19 patients when it came to resources during the pandemic's height. Elective operations, including non-urgent cardiac interventions like drug-eluting balloon angioplasty, had to be postponed or cancelled as a result. As a result, the number of procedures performed on the market for these devices decreased. Elective operations and non-urgent interventions showed a steady recovery as vaccination rates rose and healthcare systems adjusted to the epidemic. As a result of several healthcare institutions starting up again, there was an increase in demand for cardiovascular treatments, especially those requiring balloon catheters that release medication.
The coronary artery balloon catheters segment is expected to be the largest during the forecast period
The coronary artery balloon catheters segment is estimated to have a lucrative growth, as these gadgets are intended to unblock or widen coronary arteries in order to replenish blood supply to the heart muscle. In particular, drug-eluting balloon catheters are a kind of catheter that, in order to avoid restenosis, provide medication right to the location of an arterial blockage. Moreover these are becoming more and more popular; as these devices are driven by factors like the need for less invasive procedures, the prevalence of cardiovascular diseases rising, and the fact that drug-eluting balloons reduce restenosis rates more effectively than traditional angioplasty which drives the growth of the market.
The paclitaxel segment is expected to have the highest CAGR during the forecast period
The paclitaxel segment is anticipated to witness the highest CAGR growth during the forecast period, because its usage in drug-eluting balloon (DEB) catheters has drawn a lot of attention and investigation because of worries about its safety, especially in light of possible long-term consequences and a link to higher death rates in patients with peripheral artery disease (PAD). Furthermore, drug-eluting balloon catheters and other paclitaxel-coated goods have seen changes in their market dynamics due to safety concerns surrounding these devices. Thus increased scrutiny, modifications to clinical procedures and conversations about patient selection and long-term safety monitoring have resulted from it.
Region with largest share:North America is projected to hold the largest market share during the forecast period owing to the availability of several large manufacturers, the introduction of new, technologically sophisticated equipment, and advantageous reimbursement policies are all key contributors to the market share that is seen in North America. For instance, according to estimates from the American Heart Association, more than 500,000 percutaneous coronary procedures including percutaneous transluminal coronary interventions are performed in the United States each year.
Region with highest CAGR:Asia Pacific is projected to have the highest CAGR over the forecast period, owing to both the rise in healthcare costs and the prevalence of cardiovascular diseases. According to Biomedcentral, almost one in five Chinese people suffer from cardiovascular disease. Furthermore, it is projected that growing disposable income and an older population in nations like China and Japan would fuel demand in the area. The growth of health tourism in developing nations is also contributing to the industry's progress in this sector.
Key players in the marketSome of the key players profiled in the Drug-eluting Balloon Catheters Market include Aachen Resonance GmbH, B. Braun Melsungen AG, Becton, Dickinson and Company, Biotronik AG, iVascular S.L.U., Lepu Medical Technology (Beijing) Co. Ltd., MedAlliance, Medtronic plc, Biosensors International, Eurocor GmbH, Zhejiang Barty Medical Technology Co.Ltd, Cook Group Incorporated, Terumo Corporation, SurModics Inc, Koninklijke Philips NV, Jotech GmbH, MicroPort Scientific Corporation, Cordis Corporation, Cardionovum GmbH and Abbott Laboratories
Key Developments:In November 2023, BD launched a new, advanced ultrasound system designed to help improve clinician efficiency when placing peripherally inserted central catheters (PICCs), central venous catheters, IV lines and other vascular access devices.
In October 2023, Philips OneBlade Partners with College Rivals for an Epic Gaming Journey Enabling Gen Z to ‘Move Fearlessly’ this is the third strategic partnership in a year that aims to strengthen the brand’s commitment to reaching the GenZ audience.
In August 2023, Philips expands local manufacturing of Personal Health products in India to serve local demand, in addition to the beauty and grooming products already being made at the site.
Products Covered:
• Coronary Artery Balloon Catheters
• Peripheral Vascular Balloon Catheters
Drugs Covered:
• Sirolimus
• Paclitaxel
• Other Drugs
Materials Covered:
• Nylon
• Polyurethane
• Other Materials
End Users Covered:
• Ambulatory Surgical Centers
• Catheterization Laboratories
• Hospitals & clinics
• Other End Users
Regions Covered:
• North America
US
Canada
Mexico
• Europe
Germany
UK
Italy
France
Spain
Rest of Europe
• Asia Pacific
JapanChinaIndiaAustralia
New Zealand
South Korea
Rest of Asia Pacific• South America
Argentina
Brazil
Chile
Rest of South America
• Middle East & Africa
Saudi Arabia
UAE
Qatar
South Africa
Rest of Middle East & Africa
What our report offers:- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements